Alan Moses
About Alan Moses
Independent director at BiomX (PHGE) since October 2020; currently Class I with term expiring at the 2027 annual meeting. Age 77. Former Global Chief Medical Officer at Novo Nordisk A/S (2013–2018) with prior senior roles at Novo Nordisk since 2004; earlier SVP & CMO at Joslin Diabetes Center (1998–2004). MD from Washington University School of Medicine; NIH fellowship; endocrine/diabetes training at Tufts; studied Health Care Strategy at Harvard Business School. Expertise in clinical development and diabetes therapeutics.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Novo Nordisk A/S | Global Chief Medical Officer; prior U.S. Medical Affairs leadership roles | 2004–2018 (Global CMO 2013–2018) | Led global clinical development/medical affairs; diabetes focus |
| Joslin Diabetes Center | Senior Vice President & Chief Medical Officer | 1998–2004 | Responsible for Joslin Clinic operations |
| Beth Israel Deaconess–Harvard Medical School–MIT | Co‑founder/Director, Clinical Investigator Training Program | n/a | Training program founder in clinical investigation |
| National Institutes of Health | Research (post‑MD) | ~3 years | Early-career research training |
External Roles
| Organization | Type | Role | Since |
|---|---|---|---|
| Chemomab Therapeutics Ltd. (CMMB) | Public company | Director | March 2021 |
| Joslin Diabetes Center | Non‑profit/academic | Board member | December 2021 |
| diaTribe Foundation | Non‑profit | Chairman of the Board | As disclosed in 2024 proxy |
| JDRF Greater New England | Non‑profit | Board member | As disclosed in 2024 proxy |
Board Governance
- Independence: BiomX lists Dr. Moses as an independent director under NYSE American and SEC standards. Independent directors meet in executive session; six such sessions were held in 2024.
- Committee assignments (2024 activity): Compensation Committee (Chair); not a member of Audit or Nominating & Corporate Governance.
- Board structure: Classified/staggered board; Moses is Class I (term to 2027). Independent Chairman (Dr. Russell Greig).
- Attendance: Board met 22 times in 2024; all incumbent directors attended ≥75% of meetings/committees served. Note: except for the CEO, directors did not attend the 2024 annual meeting (potential engagement concern).
Committee meeting cadence (FY2024):
| Committee | Meetings/Actions by Written Consent |
|---|---|
| Audit | 6 |
| Compensation | 2 |
| Nominating & Corporate Governance | 2 |
- Compensation Committee practices under Moses (Chair): CEO excluded from deliberations on his pay; independent consultant (Aon) engaged. In 2023 Aon advised on option exchange/repricing under the Company’s plans (potential red flag); in 2024 Aon supported market data and LTI guidelines.
Fixed Compensation
Director compensation framework:
- Annual cash retainer: $35,000
- Additional annual retainers: Audit member $7,500; Compensation member $5,000; Nominating member $4,000
- Chair retainers: Audit Chair $15,000; Compensation Chair $10,000; Nominating Chair $8,000
- Board Chair: $100,000 (inclusive of committee roles); paid quarterly; reasonable expenses reimbursed.
Director cash and option compensation (Moses):
| Year | Fees Earned/Paid in Cash ($) | Option Awards (Grant‑Date Fair Value, $) | Total ($) |
|---|---|---|---|
| 2023 | 47,560 | 33,873 | 81,433 |
| 2024 | 45,824 | 29,214 | 75,038 |
Performance Compensation
- Vehicle: Annual stock option awards to non‑employee directors (no PSUs/RSUs disclosed for directors).
- Vesting schedule: 25% on first anniversary of grant; remainder in 12 equal quarterly installments, subject to continued service.
- 2024 grant framework: 17,600 options to continuing non‑employee directors; 26,400 to newly appointed directors; 35,200 to Board Chair.
- Outstanding awards (as of 12/31/2024): Moses held 26,870 options, of which 6,227 were exercisable/vested.
Option metrics summary:
| Metric | Details |
|---|---|
| Award type | Time‑based stock options (no performance metrics disclosed) |
| 2024 grant framework | 17,600 (continuing); 26,400 (new directors); 35,200 (Chair) |
| Vesting | 25% at 1 year; balance quarterly over 3 years |
| Moses options outstanding (12/31/2024) | 26,870 total; 6,227 exercisable/vested |
Other Directorships & Interlocks
| Company | Ticker | Role | Potential Interlocks/Notes |
|---|---|---|---|
| Chemomab Therapeutics | CMMB | Director | None with PHGE customers/suppliers disclosed |
| Non‑profit roles (diaTribe, JDRF) | — | Board roles | Not commercial; governance network relevance only |
No related‑party transactions involving Dr. Moses were disclosed; related‑party transactions noted involved certain >5% stockholders (e.g., CFF, OrbiMed, Telmina) in financings.
Expertise & Qualifications
- Clinical development leadership in pharma; deep domain expertise in diabetes therapeutics.
- Medical and research training (MD; NIH; endocrinology fellowship); academic program leadership.
- Independent director with Compensation Committee chair experience; committee uses an independent consultant and administers clawback policy.
Equity Ownership
Latest beneficial ownership:
| Date (Record) | Shares Beneficially Owned | % of Class |
|---|---|---|
| Aug 22, 2025 | 13,850 | <1% |
| Mar 17, 2025 | 7,582 | <1% |
| Jun 12, 2024 | 60,444 | <1% |
Options outstanding (as of Dec 31, 2024):
| Holder | Total Options Granted | Exercisable/Vested |
|---|---|---|
| Alan Moses | 26,870 | 6,227 |
Policy notes:
- Insider trading policy with prohibition against pledging and anti‑hedging provisions.
- No director stock ownership guidelines disclosed in the cited materials.
Governance Assessment
-
Strengths:
- Independent director; serves as Chair of Compensation Committee, which excludes CEO from his pay deliberations and uses an independent consultant.
- Board chaired by an independent director; independent‑only executive sessions held regularly (six in 2024).
- All directors achieved ≥75% attendance in 2024; committee activity documented.
-
Alignment and incentives:
- Director pay mix blends cash retainers with time‑based option awards; Moses total director compensation was $75,038 in 2024 (cash $45,824; options $29,214).
- Modest direct equity ownership (<1%); options outstanding with multi‑year vesting create ongoing alignment, but lack of performance‑conditioned equity for directors limits pay‑for‑performance sensitivity at the board level.
-
Risks/Red flags to monitor:
- Option exchange/repricing activity overseen by the Compensation Committee in 2023 (with Aon advising) is a governance red flag if repeated or not well‑justified; continued transparency warranted.
- Board is staggered (classified), which can reduce director accountability to shareholders and slow refreshment.
- Director annual meeting attendance: aside from the CEO, directors did not attend the 2024 annual meeting; while not a policy requirement, it may be perceived as lower shareholder engagement.
-
Conflicts and related‑party exposure:
- No related‑party transactions involving Dr. Moses disclosed; 2023–2024 related‑party financings involved certain major stockholders, not directors.
-
Policies:
- Clawback policy administered by Compensation Committee; insider policy includes prohibition on pledging and anti‑hedging.